Denali Therapeutics Inc. announced that Erik Harris has joined the Board of Directors. Mr. Harris' extensive biotech leadership and pharmaceutical experience includes 20 years in all aspects of commercial operations and achieving successful product launches in multiple therapeutic areas, including neurological and rare diseases. Erik Harris currently serves as the Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of a diverse portfolio of therapies for patients with rare and ultra-rare genetic diseases.

Mr. Harris joined Ultragenyx in 2017 as Senior Vice President and Head of North American Commercial Operations. Earlier in his career he held positions in the commercial organizations at Crescendo Bioscience, Intermune, Elan Pharmaceuticals Inc., Genentech Inc., and Bristol Myers Squibb Company. In addition to the launch of Ultragenyx's Crysvita®, Mepsevii®, and Dojolvi®, Mr. Harris has been involved in the launches of Tarceva®, Tysabri® and Vectra-DA®.

To begin his professional career, Mr. Harris served as a Lieutenant Commander in Naval Aviation and Congressional Fellow for the United States Navy. Mr. Harris received his Masters of Business Administration at the Wharton School of Business, and Bachelor of Science at the United States Naval Academy.